In reversal, European committee says combo of Genentech's Avastin and Roche chemo agent should be approved

Roche’s best-selling cancer drug Avastin should be approved in combination with the chemotherapy agent Xeloda as a first-line treatment for women with metastatic breast cancer, a committee that advises European regulators said in a reversal.
The “positive opinion” from the Committee for Medicinal Products for Human Use, or CHMP, is an important step toward expanding Avastin’s use in Europe, where the drug already is approved in combination with paclitaxel as a first-line treatment for women who can’t take chemotherapy options such as taxanes and anthracyclines.